Provider

Medical tech company Medtronic has just landed FDA clearance on its Deep Brain Stimulation (DBS) Clinical Programmer and ActivaProgramming application.

The FDA has granted Isreal-based DreaMed Diabetes a de novo request for its artificial intelligence-powered software for providers managing patients with Type 1 diabetes.

In the last few years consumer genomics has grown in both its offerings and legitimacy.

DyAnsys, a medical device company specializing in the autonomic nervous system, announced this week that it has received FDA approval for a wearable auricular neurostimulation device designed to treat symptoms of opioid withdrawal.

The past month has seen a succession of publications offering support for Click Therapeutics’ digital offering for patients with major depressive disorder (MDD).

A little bit of cash paired with a wearable activity tracker could be key in motivating people with ischemic heart disease to stay active.

Patients of doctors who participated in a Veteran Affairs-run telemedicine consultation program were 54 percent more likely to survive chronic liver disease than a matched cohort of patients of non-participating doctors, according to a new retrospective study from the University of Michigan.

The Centers for Medicare and Medicaid Services will reverse a longstanding unpopular position on reimbursement for smartphone-connected continuous glucose monitors, CMS announced yesterday.

When healthcare communications firm Spok first began investigating the prevalence of mobile strategies in 2012, only a third of survey respondents reported that their organization had a formalized strategy in place.

A clinical review, published in Evidence Based Mental Health Month, suggests numerous issues, including poor app design and privacy concerns, have contributed to a low engagement rate for mental health apps.